ASX-Dividend-Report-Banner

TraceLink Named to 2024 RXinsider Pharmacy500 List

May 09, 2024 02:53 AM AEST | By Cision
 TraceLink Named to 2024 RXinsider Pharmacy500 List
Image source: Kalkine Media

BOSTON, May 9, 2024 /PRNewswire/ -- TraceLink, a leader in end-to-end digital supply chain solutions, is proud to announce its inclusion in the Pharmacy500 list for 2024 by RXinsider. This recognition places TraceLink among the most impactful pharmacy supply chain companies in the United States, acknowledged for its significant influence on dispensing pharmacies over the past year.

Specializing in a suite of services that address critical industry needs—including Drug Supply Chain Security Act (DSCSA) compliance, digitalized recall management, drug shortage prediction, product master data sharing, serialized product verification, and more —TraceLink provides comprehensive solutions that enhance the safety, efficiency, and responsiveness of the pharmaceutical supply chain. The Pharmacy500 award celebrates those companies that have made notable contributions to the pharmacy sector, particularly in operational areas that impact profitability and patient care.

Shabbir Dahod, President and CEO of TraceLink, expressed his enthusiasm for this accolade: "Our recognition in the Pharmacy500 highlights TraceLink's dedication to transforming the pharmacy supply chain with cutting-edge technology. Our comprehensive solutions are crafted to help pharmacies adapt to the ever-changing needs of healthcare, enhancing both their operational efficiency and the quality of care they provide."

TraceLink has long been committed to pharmacy operational excellence with over 400+ pharmacies and health systems customers, 100+ whom are currently exchanging DSCSA EPCIS transactions in advance of the end of the stabilization period. Since August 2023, over 3 million DSCSA EPCIS transactions have been processed, including 2 million by dispenser customers in the last two months alone as we prepare our customer base and 500 MAHs and wholesalers with EPCIS transaction integrations.

Gregory Cianfarani, RPh, Founder and CEO of RXinsider, emphasized the significance of recognizing technology in pharmacy: "With such a historical focus on the clinical aspects of pharmacy, it's exciting to recognize a segment of the supply chain that impacts pharmacies from an operational standpoint, enabling pharmacies to operate efficiently and profitably while producing exceptional and innovative pharmaceutical care."

This accolade is a reflection of TraceLink's ongoing efforts to support the pharmacy industry in navigating modern challenges by providing scalable, secure, and integrative supply chain solutions.

For more information about TraceLink and its impact on the pharmacy supply chain, please visit TraceLink's website .

About TraceLink Inc.:

TraceLink Inc. is the leading digital network platform company, enabling end-to-end product orchestration by connecting more than 290,000 healthcare and life sciences entities through its B2N Integrate-Once™ network. Leading businesses trust TraceLink to deliver complete global connectivity, visibility, and traceability of pharmaceuticals, ensuring that every patient gets the medicines they need when needed, safely and securely.

About Rxinsider:

RXinsider is a B2B multimedia publishing and technology company focused on the "business of pharmacy". They are the leading resource for pharmacy management to learn about the products and services that support pharmacies and patient care. The Pharmacy500 is awarded to 500 pharmacy supply chain businesses and associations that significantly impacted dispensing pharmacies in the U.S. over the past year.

 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.